Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORWARD: AXS-14 in Fibromyalgia
NCT07398417Phase 3Recruiting
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Jan 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of esreboxetine in fibromyalgia (FM), sponsored by Axsome Therapeutics, Inc.. Started Jan 2026; status: recruiting.
02
Drugs
esreboxetine
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT07398417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07398417.